Exploring QSARs of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Tyrosine Kinase Inhibitors by MLR, PLS and PC-ANN

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|19|12|2237-2244

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.12, 2013-01, pp. : 2237-2244

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vascular endothelial growth factor tyrosine kinase inhibitors

By  

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 6, 2004-06 ,pp. : 921-924

Informa Healthcare

Access to resources Recommend Favorite

Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 11, Iss. 6, 2004-03 ,pp. : 731-745

Bentham Science Publishers

Access to resources Recommend Favorite

Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 2, 2015-03 ,pp. : 137-142

John Wiley & Sons Inc

Access to resources Recommend Favorite

Putting the Brakes on Cancer: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

By  

Pharmaceutical Innovation, Vol. 12, Iss. 1, 2002-12 ,pp. : 12-15

Adis International

Access to resources Recommend Favorite

Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect

By  

Current Medicinal Chemistry, Vol. 23, Iss. 10, 2016-03 ,pp. : 1000-1040

Bentham Science Publishers

Access to resources Recommend Favorite